Adalimumab (Humira®) Induced Recurrent Peritonsillar Abscess in A Patient Received Three Different Anti-TNF Therapies: A Case Report

Anti-tumor necrosis factor agents are widely used in treating ankylosing spondylitis, but they increase the risk of infection by suppressing the immune response. Therefore, physicians should be careful about recurrent infections in patients under anti-tumor necrosis factor agents.

Detalles Bibliográficos
Autores principales: Vural, Sevilay, Kuşdoğan, Mikail, Kaya, Hasan Burak, İkiz, Venhar, Albayrak, Levent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2022
Materias:
Clinical Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235369/
https://www.ncbi.nlm.nih.gov/pubmed/37274971
http://dx.doi.org/10.1007/s12070-022-03203-0
_version_ 1785052667079294976
author Vural, Sevilay
Kuşdoğan, Mikail
Kaya, Hasan Burak
İkiz, Venhar
Albayrak, Levent
author_facet Vural, Sevilay
Kuşdoğan, Mikail
Kaya, Hasan Burak
İkiz, Venhar
Albayrak, Levent
author_sort Vural, Sevilay
collection PubMed
description Anti-tumor necrosis factor agents are widely used in treating ankylosing spondylitis, but they increase the risk of infection by suppressing the immune response. Therefore, physicians should be careful about recurrent infections in patients under anti-tumor necrosis factor agents.
format Online
Article
Text
id pubmed-10235369
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer India
record_format MEDLINE/PubMed
spelling pubmed-102353692023-06-03 Adalimumab (Humira®) Induced Recurrent Peritonsillar Abscess in A Patient Received Three Different Anti-TNF Therapies: A Case Report Vural, Sevilay Kuşdoğan, Mikail Kaya, Hasan Burak İkiz, Venhar Albayrak, Levent Indian J Otolaryngol Head Neck Surg Clinical Report Anti-tumor necrosis factor agents are widely used in treating ankylosing spondylitis, but they increase the risk of infection by suppressing the immune response. Therefore, physicians should be careful about recurrent infections in patients under anti-tumor necrosis factor agents. Springer India 2022-12-06 2023-06 /pmc/articles/PMC10235369/ /pubmed/37274971 http://dx.doi.org/10.1007/s12070-022-03203-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Clinical Report
Vural, Sevilay
Kuşdoğan, Mikail
Kaya, Hasan Burak
İkiz, Venhar
Albayrak, Levent
Adalimumab (Humira®) Induced Recurrent Peritonsillar Abscess in A Patient Received Three Different Anti-TNF Therapies: A Case Report
title Adalimumab (Humira®) Induced Recurrent Peritonsillar Abscess in A Patient Received Three Different Anti-TNF Therapies: A Case Report
title_full Adalimumab (Humira®) Induced Recurrent Peritonsillar Abscess in A Patient Received Three Different Anti-TNF Therapies: A Case Report
title_fullStr Adalimumab (Humira®) Induced Recurrent Peritonsillar Abscess in A Patient Received Three Different Anti-TNF Therapies: A Case Report
title_full_unstemmed Adalimumab (Humira®) Induced Recurrent Peritonsillar Abscess in A Patient Received Three Different Anti-TNF Therapies: A Case Report
title_short Adalimumab (Humira®) Induced Recurrent Peritonsillar Abscess in A Patient Received Three Different Anti-TNF Therapies: A Case Report
title_sort adalimumab (humira®) induced recurrent peritonsillar abscess in a patient received three different anti-tnf therapies: a case report
topic Clinical Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235369/
https://www.ncbi.nlm.nih.gov/pubmed/37274971
http://dx.doi.org/10.1007/s12070-022-03203-0
work_keys_str_mv AT vuralsevilay adalimumabhumirainducedrecurrentperitonsillarabscessinapatientreceivedthreedifferentantitnftherapiesacasereport
AT kusdoganmikail adalimumabhumirainducedrecurrentperitonsillarabscessinapatientreceivedthreedifferentantitnftherapiesacasereport
AT kayahasanburak adalimumabhumirainducedrecurrentperitonsillarabscessinapatientreceivedthreedifferentantitnftherapiesacasereport
AT ikizvenhar adalimumabhumirainducedrecurrentperitonsillarabscessinapatientreceivedthreedifferentantitnftherapiesacasereport
AT albayraklevent adalimumabhumirainducedrecurrentperitonsillarabscessinapatientreceivedthreedifferentantitnftherapiesacasereport

Ejemplares similares